Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976643 | 0.83 | CHRNB4 (0.41) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL6979232 | 0.83 | CHRNB4 (0.41) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL6959571 | 0.81 | CHRNB4 (0.37) | CHRNB4CHRNA3CCNE1CDK2CDK1 | |
| SCHEMBL6976822 | 0.79 | LTA4H (0.34) | — | |
| SCHEMBL6980143 | 0.79 | CHRNB4 (0.38) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA5 | |
| SCHEMBL6959496 | 0.78 | CCNE1 (0.35) | CHRNB4CHRNA3CCNE1CDK2CDK1 | |
| SCHEMBL6955594 | 0.78 | CCNE1 (0.35) | CHRNB4CHRNA3CCNE1CDK2CDK1 | |
| SCHEMBL19121074 | 0.78 | CCNE1 (0.35) | CHRNB4CHRNA3CCNE1CDK2CDK1 | |
| SCHEMBL9975285 | 0.77 | IRAK4 (0.39) | IRAK4 | |
| SCHEMBL9975260 | 0.77 | IRAK4 (0.39) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | CHRNB4 1621/4885CHRNA3 1725/4885CCNE1 631/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | CHRNB4 1621/4885CHRNA3 1725/4885CCNE1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.